Sandwich, UK - 9 March 2026: SignaCor Therapeutics has been named the winner of Discovery Park's startup growth programme for innovations in cardiovascular health, securing £250k in funding from venture capital firm Zinc. This investment forms part of a £1M seed round expected to close in April.
What to Expect at the 8th T-Cell Engager Therapeutics Summit?
For over 30 years, UCLB has built a sustained engine of commercial success, turning exceptional UCL research into ventures and licensing deals across every discipline.
The UCL 2026 Impact Report demonstrates how this work is having real-world impact, from changing patients’ lives with new personalised treatments for leukaemia, to making businesses more efficient with the use of AI tools, to empowering communities to have their voices heard with data and maps.
Are you passionate about making life science life changing and delivering impact for patients? We want to hear from you.
The Scientist, Antibody Discovery role will be focused on screening and subsequent characterisation of monoclonal antibodies using a range of assay technologies.
PHILADELPHIA, PA – February 26, 2026 – Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.
We are seeking a talented and creative Senior Bioinformatician with a passion for using computational advances to prioritise and advance high-potential therapeutic antibodies and targets from Alchemab’s discovery platform through to the clinic.
Reporting into the Principal Bioinformatician, the Senior Bioinformatician will take a lead role in shaping and executing Alchemab’s computational target evaluation strategy by:
Healx is an AI-powered tech bio company that is redesigning drug discovery. With 10,000 rare diseases affecting 400 million people globally, 90% of which have no approved treatment, Healx is on a mission to pioneer the next generation of drug discovery to help rare disease patients in need. We combine data, artificial intelligence and deep pharmacology expertise to develop treatments more quickly and cheaply than traditional drug discovery.
Healx is an AI-powered tech bio company that is redesigning drug discovery. With 10,000 rare diseases affecting 400 million people globally, 90% of which have no approved treatment, Healx is on a mission to pioneer the next generation of drug discovery to help rare disease patients in need. We combine data, artificial intelligence and deep pharmacology expertise to develop treatments more quickly and cheaply than traditional drug discovery.
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
At AstraZeneca's Oncology R&D department, we follow the science and pioneer new frontiers. We are a team dedicated to Oncology Cell Therapies, with an ambition to eliminate cancer as a cause of death. Our big vision unites and inspires us. With multiple indications and cutting-edge therapeutic modalities at all stages of our innovative pipeline, we keep pushing forward. Fusing groundbreaking science with the latest technology to achieve breakthroughs.